A platinum complex and its liposome and application
Through platinum complexes, amphiphilic compounds and liposome technologies, the problems of toxic side effects and insufficient efficacy of platinum drugs were solved, and platinum anti-tumor drugs with high drug loading and low toxicity were achieved, which significantly improved the efficacy and Security.
Patent Information
- Application Number
- CN202010552541.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-06-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-06-17
AI Technical Summary
The existing platinum anti-tumor drugs have serious toxic and side effects due to their non-specific activity, which is difficult to use in large doses and long-term clinically, and have insufficient efficacy. How to develop high drug load, high activity and low toxicity platinum anti-tumor drugs to become challenge.
The specific platinum complex forms coordination bonds with amphiphilic compounds, combines liposome technology, prepares platinum complexes through esterification and alcoholylation reactions, and binds them to lipid membrane materials combined with phospholipids or cholesterol. Liposomes with high encapsulation rates and high drug loading volumes are formed, and the pH sensitivity of the carboxyl group is used to promote the release of drugs in tumor tissues.
It significantly reduces the toxic side effects of the drug, especially nephrotoxicity, improves the efficacy and drug loading, extends the retention time of the drug in the body, and enhances the inhibitory effect on tumors.
Smart Images

Figure CN113801167B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medicine, and in particular to a platinum complex and a liposome thereof and application thereof. Background Art
[0002] Platinum compounds have some unique and excellent physical and chemical properties, play an important role in high-tech, and are known as the vitamins of modern industry. Therefore, since Rosenborg first discovered the anti-tumor activity of platinum compounds in the 1960s, their research and application have developed rapidly. At present, cisplatin, carboplatin, nedaplatin, epplatin, cycloplatin, oxaliplatin, levoplatin, heptaplatin, etc. have been successfully developed, and new platinum complexes are still being synthesized and applied in clinical trials. Although these platinum anti-tumor drugs have certain anti-tumor activity, few drugs with better efficacy than cisplatin have been found. According to statistics, in my country's anti-tumor chemotherapy treatment regimens, cisplatin-based or cisplatin-involved regimens account for 70% to 80% of all chemotherapy regimens. Platinum-based anti-tumor drugs are broad-spectrum anti-cancer drugs with the advantages of strong effects, high activity, no cross-resistance, and easy compatibility with other anti-tumor drugs. However, their severe side effects (including nephrotoxicity, neurotoxicity, ototoxicity, gastrointestinal toxicity, etc.) and drug resistance greatly limit their high-dose and long-term use in clinical practice.
[0003] Since the non-specificity brought by the broad-spectrum anti-tumor activity is the main reason for the toxic side effects of platinum drugs, the search for platinum anti-tumor drugs with low toxic side effects while retaining anti-tumor activity has become the main research direction. To this end, pharmacists in various countries are committed to the synthesis of new platinum compounds and targeted drug delivery systems (such as liposomes, nanoparticles, micelles, vesicles, etc.), hoping to obtain highly active and low-toxic anti-tumor drugs.
[0004] At present, a variety of anti-tumor drugs developed by platinum-based drugs have been announced. Inhaled lipid-complexed cisplatin (ILC) is a cisplatin liposome complex for lung inhalation developed by my country's Intergene Technology Co., Ltd. [Patent, USA: 20140065205A1, 2014]. It is a new dosage form of cisplatin that can be continuously released, encapsulated by nanoliposomes, and can be administered by aerosol inhalation. In the Phase I lung cancer trial and the Phase Ib / IIa clinical osteosarcoma lung metastasis trial completed in Europe and the United States, it showed excellent safety and good therapeutic effects. With the increase of treatment cycles, the patient's lung lesion tumors continue to shrink. In addition, some researchers have prepared anti-tumor drugs into liposomes, hoping to achieve the purpose of reducing toxicity and improving efficacy by changing the distribution of the drug in the body.
[0005] However, platinum anti-tumor drugs using liposomes as carriers still face many challenges. Taking cisplatin as an example, SPI-77 is a long-circulating cisplatin liposome developed by Alza using passive drug loading, which has good pharmacokinetic properties, such as its t 1 / 2 About 16 hours, which is 66 times that of cisplatin, prolonging its circulation time in the blood. In addition, compared with cisplatin, its plasma AUC increases sixty times, Cmax increases three times, the amount of platinum in the kidney decreases four times, and the tumor AUC increases 28 times [Cancer Chemother Pharmacol, 1999, 43(1): 1–7]. However, SPI-77 lacks antitumor activity in Phase II clinical trials for the treatment of inoperable head and neck cancer [Ann Oncol, 2001, 12(4): 493–496], advanced non-small cell lung cancer [Br J Cancer, 2006, 95(7): 822–828], and platinum-sensitive recurrent ovarian cancer [Anticancer Res, 2010, 30(2): 541–545]. It is believed that hydrophilic drugs such as cisplatin cannot pass through the phospholipid membrane smoothly, and only when liposomes release the encapsulated drugs in tumor tissues can they have antitumor activity. Lipoplatin is another long-circulating cisplatin liposome developed by Regulon. It is a reverse micelle formed by cisplatin and dipalmitoylphosphatidylglycerol (DPPG) and then encapsulated in a lipid membrane. Clinical studies have shown that Lipoplatin can not only reduce nephrotoxicity, neurotoxicity, ototoxicity and bone marrow toxicity, but also has an efficacy comparable to or even superior to cisplatin. Its accumulation in solid tumors is 10-200 times higher than that in normal tissues [Anticancer Res, 2005, 25(4): 3031-3039]. Therefore, how to prepare platinum anti-tumor drugs with high drug loading, high activity and low toxicity is still a huge challenge facing pharmaceutical workers. Summary of the invention
[0006] The purpose of the present invention is to provide a platinum complex and liposomes thereof. The platinum complex and the liposomes prepared therefrom not only have high encapsulation efficiency and drug loading, but also significantly reduce toxicity, especially nephrotoxicity, and the preparation process is simple and controllable, which is conducive to industrialized expansion of production.
[0007] The present invention provides platinum complexes having structures shown in Formula I-a to Formula I-b:
[0008]
[0009] R 1 Selected from -C n H 2n -、-C n H 2n-2 -、-Ar-Cn H 2n -、Ar-C n H 2n-2 -、-Ar-OC n H 2n -、Ar-OC n H 2n-2 -, n = 0 to 22;
[0010] Wherein, Ar is a 6-14-membered monocyclic, bicyclic, or tricyclic carbon ring system, and at least one ring system is aromatic; preferably phenylene, naphthyl, anthracene;
[0011] R 2 Selected from -H, -C b H 2b-1 , -C b H 2b+1 、-Ar-C b H 2b-1 、-Ar-C b H 2b+1 、-Ar-OC b H 2b-1 Or-Ar-OC b H 2b+1 , b = 1 to 22;
[0012] Wherein, Ar is a 6-14-membered monocyclic, bicyclic, or tricyclic carbon ring system, and at least one ring system is aromatic; preferably phenylene, naphthyl, anthracene;
[0013] Wherein, any H connected to C may be substituted by a substituent;
[0014] Wherein, the substituent is -OH, -NH 2 , -COOH, halogen or -Ar; Ar is as described above;
[0015] In an embodiment of the present invention,
[0016] R 1 Selected from -C n H 2n -or-C n H 2n-2 , n=1 to 10; n is preferably 1 to 4;
[0017] R 2 Selected from -C b H 2b-1 or -C b H 2b+1 , b=8~18;
[0018] In an embodiment of the present invention,
[0019] R 1 Selected from -CH 2 -、
[0020] R 2 Selected from -C b H 2b-1 or -C b H 2b+1 , b=12~18.
[0021] In some embodiments,
[0022] R 1 for
[0023] R 2 For -(CH 2 ) 17 CH 3 .
[0024] The present invention also provides platinum complexes having structures shown in Formula I-c to Formula I-d:
[0025]
[0026] R 3 Selected from -NH 2 、-(CH 2 ) c -NHCO-(CH 2 ) d CH 3 、-OH、-O-CO-(CH 2 ) c CH 3 , -C d H 2d -OH, -C d H 2d-2 -OH, -C d H 2d -COOH, -C d H 2d-2 -COOH, -C d H 2d -O-CO-(CH 2 ) c -CH 3 ,, c=1~21, d=1~8;
[0027] R 4 Selected from -H, -C e H 2e-1 , -C e H 2e+1 、-Ar-C eH 2e-1 、-Ar-C e H 2e+1 、-Ar-OC e H 2e-1 Or-Ar-OC e H 2e+1 , e = 1 to 22;
[0028] in,
[0029] Ar is a 6-14 membered monocyclic, bicyclic, or tricyclic carbon ring system, and at least one ring system is aromatic; preferably phenylene, naphthyl, anthracene;
[0030] m = 0 to 10;
[0031] Wherein, any H connected to C may be substituted by a substituent;
[0032] Wherein, the substituent is -OH, -NH 2 , -COOH, halogen or -Ar.
[0033] In an embodiment of the present invention,
[0034] m = 0 to 8;
[0035] R 3 Selected from -NH 2 、-(CH 2 ) c -NHCO-(CH 2 ) d CH 3 、-OH、-O-CO-(CH 2 ) c CH 3 , -C d H 2d -OH, -C d H 2d -COOH, -C d H 2d-2 -COOH, -C d H 2d -O-CO-(CH 2 ) c -CH 3 , c=8~20, d=1~6.
[0036] R 4 Selected from -H, -C e H 2e-1 or -C e H 2e+1 , e=8~20.
[0037] In an embodiment of the present invention,
[0038] m = 0 to 6;
[0039] R 3 Selected from -OH, -(CH 2 ) 2 -COOH, -(CH 2 ) 4 -O-CO-(CH 2 ) 14 CH 3 or -O-CO-(CH 2 ) c -CH 3 ;
[0040] R 4 Selected from -C e H 2e+1 , e = 8 to 18;
[0041] In some embodiments,
[0042] m=0;
[0043] R 3 For -(CH 2 ) 2 -COOH;
[0044] R 4 For -C e H 2e+1 , e=8~18.
[0045] In some embodiments,
[0046] m = 1 to 6;
[0047] R 3 -O-CO-(CH 2 ) c -CH 3 , c = 8-20;
[0048] R 4 For -C e H 2e+1 , e=8~18.
[0049] The present invention also provides an amphiphilic compound having a structure shown in Formula II, which can be used to prepare a platinum complex:
[0050]
[0051] R 5 Selected from -H, -C f H 2f-1 , -C f H 2f+1、-Ar-C f H 2f-1 、-Ar-C f H 2f+1 、-Ar-OC f H 2f-1 Or-Ar-OC f H 2f+1 , f = 1 to 22;
[0052] R 6 Selected from -C g H 2g-1 , -C g H 2g-2 or -C g H 2g -O-, g = 1 to 8;
[0053] R 7 Selected from -OH, -C h H 2h-1 , -C h H 2h+1 、-Ar-C h H 2h-1 、-Ar-C h H 2h+1 、-Ar-OC h H 2h-1 Or-Ar-OC h H 2h+1 , h = 1 to 22;
[0054] Ar is a monocyclic, bicyclic, or tricyclic carbon ring system containing 6 to 14 ring members, such as phenylene, naphthyl, anthracene, etc., and at least one ring system is aromatic;
[0055] Wherein, any H connected to C may be substituted by a substituent;
[0056] Wherein, the substituent is -OH, -NH 2 , -COOH, halogen or -Ar;
[0057] R 6 and R 7 The structure of hydroxyl radicals includes at least one -COOH.
[0058] or R 6 and R 7 The structure of the compound includes at least one carboxylate ion such as -COONa, -COOK, etc.
[0059] In the amphiphilic compound provided by the present invention,
[0060] R 5 For -C f H 2f+1, R 6 for R 7 is -OH;
[0061] or R 5 For -C f H 2f+1 , R 6 for R 7 is -OH;
[0062] or R 5 For -C f H 2f+1 , R 6 for R 7 For -C h H 2h+1 ;
[0063] R 5 For -C f H 2f+1 , R 6 for R 7 For -C h H 2h+1 ;
[0064] f=8~18; g=2~6; h=8~18.
[0065] The structural formulas of the amphiphilic compounds provided by the present invention are shown in Formula II-a to Formula II-b:
[0066]
[0067] The amphiphilic compounds provided by the present invention also include carboxylates of formula II-a and formula II-b.
[0068] The carboxylates of formula II-a and II-b included in the present invention include sodium stearyl fumarate, hard sodium maleate, hard sodium succinate, sodium laurate maleate, potassium myristic maleate, potassium palmitate (but not limited to such salts), and also include organic base salts of these compounds.
[0069] The platinum complex provided by the present invention is prepared by combining platinum compounds such as cisplatin, carboplatin, lobaplatin, oxaliplatin, nedaplatin (but not limited to these platinum drugs) with a coordination bond formed by a carboxyl group and a carbonyl group of an ester bond in an amphiphilic compound. The present invention has no special requirements for the reaction conditions, and any reaction conditions known in the art for preparing platinum complexes can be used.
[0070] The amphiphilic compound used in the platinum complexes of formula Ia and formula Ib of the present invention can be prepared by esterification reaction of a carboxyl group in a dicarboxylic acid (such as fumaric acid, maleic acid, succinic acid, etc.) or an anhydride (such as maleic anhydride, succinic anhydride, etc.) with a fatty alcohol (but not limited to this, all synthetic reactions that can generate the structure are acceptable). The amphiphilic compound in the platinum complexes of formula Ic and formula Id of the present invention is prepared by alcoholysis reaction of a fatty acyl chloride with a hydroxy acid (such as lactic acid, citric acid, salicylic acid, tartaric acid, etc., but not limited to this, and compounds with similar structures are acceptable). The present invention has no special requirements for the reaction conditions, and the reaction conditions known in the art for preparing esters by reaction of alcohol with acid, alcohol with acyl chloride are acceptable.
[0071] The present invention also provides a liposome of a platinum complex, comprising the platinum complex provided by the present invention and a lipid membrane material; the ratio of the platinum complex to the liposome membrane material is 99:1 to 1:99, and the preferred ratio is 49:51 to 5:95.
[0072] The ratio is a mass ratio, a molar ratio or a volume ratio.
[0073] In the liposome provided by the present invention, the lipid membrane material comprises a composition of phospholipids and / or cholesterol, the mass fraction of phospholipids in the membrane material is 1 to 100 parts, and the mass fraction of cholesterol is 0 to 60 parts.
[0074] In the liposome provided by the present invention, the phospholipids include one or a combination of two or more of phosphatidylcholine, soybean lecithin, hydrogenated soybean lecithin, phosphatidylinositol, phosphatidylglycerol, dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dilauroyl phosphatidic acid, dilauroylphosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, phosphatidylserine, dilauroylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, PEGylated phospholipids, etc.
[0075] The platinum complex provided by the present invention can also be added with suitable adjuvants and additives and prepared into different dosage forms using techniques known in the art, such as injections, lyophilized powders for injection, liposome suspensions, tablets, gels, implants, etc., for administration by intravenous injection, local injection, implantation, inhalation, etc.
[0076] The present invention provides a medicine for treating cancer, comprising the liposome provided by the present invention.
[0077] The present invention provides a compound of formula II structure, which has good biocompatibility, and the carboxyl group and the carbonyl group of the ester bond can be coordinated with platinum drugs, and the unstable coordination bond formed with the platinum drugs can increase the hydration rate of the drug in the body, thereby improving the drug efficacy. At the same time, the platinum complex prepared by the compound provided by the present invention can be well combined with the membrane material of the liposome, thereby improving the encapsulation rate and drug loading of the liposome. In addition, after the platinum complex is prepared by the compound provided by the present invention, it contains a carboxyl group and has pH sensitivity. In a lower pH environment (such as tumor tissue), the carboxyl group tends to be deprotonated, which is conducive to promoting the release of the drug in the tumor tissue and improving the efficacy of the drug. The liposome provided by the present invention can significantly reduce the toxic and side effects of the drug and improve the drug efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1-a 1 shows the mass spectrum of the amphiphilic compound of Example 1;
[0079] Figure 1-b 4 shows the mass spectrum of the amphiphilic compound of Example 2;
[0080] Figure 1-c 4 shows the mass spectrum of the amphiphilic compound of Example 3;
[0081] Figure 1-d 4 shows the mass spectrum of the amphiphilic compound of Example 4;
[0082] Figure 1-e 5 shows the mass spectrum of the amphiphilic compound of Example 5;
[0083] Figure 2-a The NMR spectrum of the amphiphilic compound of Example 1 is shown;
[0084] Figure 2-b The NMR spectrum of the amphiphilic compound of Example 2 is shown;
[0085] Figure 2-c The NMR spectrum of the amphiphilic compound of Example 3 is shown;
[0086] Figure 2-d The NMR spectrum of the amphiphilic compound of Example 4 is shown;
[0087] Figure 3-a 1 shows the infrared spectrum of the amphiphilic compound of Example 1;
[0088] Figure 3-b 14 shows the infrared spectrum of the amphiphilic compound of Example 2;
[0089] Figure 3-c 4 shows the infrared spectrum of the amphiphilic compound of Example 4;
[0090] Figure 3-d 4 shows the infrared spectrum of the amphiphilic compound of Example 5;
[0091] Figure 4-a 1 shows the XRD pattern of the amphiphilic compound of Example 1;
[0092] Figure 4-b 2 shows the XRD pattern of the amphiphilic compound of Example 2;
[0093] Figure 4-c 3 shows the XRD pattern of the amphiphilic compound of Example 3;
[0094] Figure 4-d 4 shows the XRD pattern of the amphiphilic compound of Example 4;
[0095] Figure 4-e 5 shows the XRD pattern of the amphiphilic compound of Example 5;
[0096] Figure 5 The electron microscopic examination image of the liposomes prepared in Example 24 is shown;
[0097] Figure 6 The particle size distribution diagram of the liposomes prepared in Example 24 is shown;
[0098] Figure 7 shows the survival rate of tumor-bearing mice (7a-7d);
[0099] Figure 8 Shown are kidney tissue sections of tumor-bearing mice;
[0100] Fig. 9 Shows the survival rate of mice in the preliminary safety evaluation;
[0101] Fig.10 Shows the body weight change rate of mice in the preliminary safety evaluation. DETAILED DESCRIPTION
[0102] The present invention provides a class of compounds and their applications, as well as a platinum complex and its liposomes. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0103] The present invention provides platinum complexes having structures shown in formulas Ia to Id:
[0104]
[0105] R 1 Selected from -C n H 2n -、-Cn H 2n-2 -, -Ar-C n H 2n -, Ar-C n H 2n-2 -, -Ar-O-C n H 2n -, Ar-O-C n H 2n-2 -, n = 0 to 22;
[0106] R 2 Selected from -H, -C b H 2b-1 、, -C b H 2b+1 、, -Ar-C b H 2b-1 、, -Ar-C b H 2b+1 、, -Ar-O-C b H 2b-1 or -Ar-O-C b H 2b+1 ,, b = 1 to 22;
[0107] R 3 Selected from -NH 2 、, -(CH 2 ) c -NHCO-(CH 2 ) d CH 3 、, -OH, -O-CO-(CH 2 ) c CH 3 、, -C d H 2d -OH, -C d H 2d-2 -OH, -C d H 2d -COOH, -C d H 2d-2 -COOH, -C d H 2d -O-CO-(CH 2 ) c -CH 3 、, c = 1 to 21, d = 1 to 8;
[0108] R 4 Selected from -H, -C e H 2e-1 、, -C e H 2e+1 、, -Ar-C e H 2e-1 、, -Ar-Ce H 2e+1 、-Ar-OC e H 2e-1 Or-Ar-OC e H 2e+1 , e = 1 to 22;
[0109] m = 0 to 10;
[0110] Wherein, any H connected to C may be substituted by a substituent;
[0111] Wherein, the substituent is -OH, -NH 2 , -COOH, halogen or -Ar.
[0112] In the present invention, -C b H 2b+1 or -C e H 2e+1 is an alkyl group, and the value of b is 1 to 22. In some embodiments, the value of b is 8 to 20. In other embodiments, b is 8 to 18 or b is 12 to 18; in other embodiments, b is 14 to 16; in some embodiments, b is 15. The value of e may be the same as or different from the value of b, and independently, the value of e is 1 to 22. In some embodiments, the value of e is 8 to 20. In other embodiments, e is 8 to 18 or e is 12 to 18; in other embodiments, e is 14 to 16; in some embodiments, e is 15. The alkyl group is a straight-chain alkyl group or a branched-chain alkyl group; in some embodiments, it is a straight-chain alkyl group. The alkyl group is a substituted or unsubstituted alkyl group. The substitution means that the H connected to any C in the alkyl group can be substituted by a substituent, and the substituent of the substituted alkyl group is -NH 2 , -OH, -COOH, halogen or -Ar. The number of substituents on any C is 1 or 2. In the present invention, -C b H 2b+1 Alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), n-propyl (n-Pr, -CH 2 CH 2 CH 3 ), isopropyl (i-Pr, -CH (CH 3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), isobutyl (i-Bu, -CH 2 CH(CH 3 )2 ), sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methylbutyl (-CH 2 CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-butyl (-C(CH 3 ) 2 CH 2 CH 3 ), 3-methylbutyl (-CH 2 CH 2 CH(CH 3 ) 2 ), 3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), n-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-hexyl (-CH(CH 3 )CH 2 CH 2 CH 2 CH 3 ), 3-hexyl (-CH(CH 2 CH 3 )CH 2 CH 2 CH 3 ), 2-methylpentyl (-CH 2 CH(CH 3 )CH 2 CH 2 CH 3 ), 2-methyl-2-pentyl (-CH(CH 3 )2 CH 2 CH 2 CH 3 ), 2-methyl-3-pentyl (-CH(CH 2 CH 3 )CH(CH 3 ) 2 ), 3-methylpentyl (-CH 2 CH 2 CH(CH 3 )CH 2 CH 3 ), 3-methyl-2-pentyl (-CH(CH 3 )CH(CH 3 )CH 2 CH 3 ), 3-methyl-3-pentyl (-CH(CH 3 )(CH 2 CH 3 ) 2 ), 4-methyl-2-pentyl (-CH(CH 3 )CH 2 CH(CH 3 ) 2 ), 4-methylpentyl (-CH 2 CH 2 CH 2 CH(CH 3 ) 2 ), 2,2-dimethylbutyl (-CH 2 C(CH 3 ) 2 CH 2 CH 3 ), 3,3-dimethyl-2-butyl (-CH(CH 3 )C(CH 3 ) 3 ), 3,3-dimethylbutyl (-CH 2 CH 2 C(CH 3 ) 3 ), 2,3-dimethylbutyl (-CH 2 CH(CH 3 )CH(CH 3 ) 2 ), 2,3-dimethyl-2-butyl (-C(CH 3 ) 2 CH(CH 3 ) 2 ), n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, and n-octadecyl.
[0113] In the present invention, -C b H 2b-1 or -C e H 2e-1 Refers to an alkenyl group in which at least one position is unsaturated, i.e. one CC is sp 2 Double bond. The value of b is 2 to 22. In some embodiments, the value of b is 8 to 20. In other embodiments, b is 8 to 18 or b is 12 to 18; in other embodiments, b is 14 to 16; in some embodiments, b is 15. The value of e may be the same as or different from the value of b, and independently, the value of e is 2 to 22. In some embodiments, the value of e is 8 to 20. In other embodiments, e is 8 to 18 or e is 12 to 18; in other embodiments, e is 14 to 16; in some embodiments, e is 15. The alkenyl group is a straight-chain alkenyl group or a branched alkenyl group, and in some embodiments, it is a straight-chain alkenyl group. The alkenyl group is a substituted or unsubstituted alkenyl group. The H attached to any C in the substituted alkenyl group may be substituted by a substituent, and the substituent of the substituted alkenyl group is -NH 2 , -OH, -COOH, halogen or -Ar. The number of substituents on any C is 1 or 2. The alkenyl group includes groups with "anti" "positive" or "E" "Z" orientations, and specific examples include, but are not limited to, vinyl (-CH=CH 2 ), propenyl, allyl (-CH 2 CH=CH 2 ), butenyl and 4-methylbutenyl, 2-pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl.
[0114] In the present invention, -Ar-C b H 2b+1 Refers to a -C bonded to a phenyl or aryl group b H 2b+1 , -Ar-C b H 2b-1 Refers to a -C bonded to a phenyl or aryl group b H 2b -1, -Ar-OC b H 2b+1 Refers to the -C connected to -Ar-O- b H 2b+1 , -Ar-OC b H 2b-1 Refers to the -C connected to -Ar-O- b H 2b -1. -Ar-C e H2e+1 Refers to a -C bonded to a phenyl or aryl group e H 2e+1 , -Ar-C e H 2e-1 Refers to a -C bonded to a phenyl or aryl group e H 2e -1, -Ar-OC e H 2e+1 Refers to the -C connected to -Ar-O- e H 2e+1 , -Ar-OC e H 2e-1 Refers to the -C connected to -Ar-O- e H 2e-1 The -Ar- represents a monocyclic, bicyclic, and tricyclic carbon ring system containing 6-14 ring members, and at least one ring system is aromatic, wherein each ring system contains 3-7 ring members, wherein there are two connection points to the rest of the molecule. -Ar- can be phenylene, naphthyl and anthracene. And the -Ar- can be substituted or unsubstituted.
[0115] In the present invention, -C n H 2n- or -C d H 2d- Refers to an alkylene group, and the value of n is 1 to 8. In some embodiments, the value of n is 1 to 6. In other embodiments, n is 1 to 4; in other embodiments, n is 2 to 4; the alkylene group is a straight chain or branched chain alkylene group; the value of d may be the same as or different from the value of n, and independently, the value of d is 1 to 8. In some embodiments, the value of d is 1 to 6. In other embodiments, d is 1 to 4; in other embodiments, d is 2 to 4; the alkylene group is a straight chain or branched chain alkylene group; in some embodiments, it is a straight chain alkylene group. The alkylene group is a substituted or unsubstituted alkylene group. The substitution refers to that the H connected to any C in the alkylene group may be substituted by a substituent, and the substituent of the substituted alkyl group is -NH 2 , -OH, -COOH or -Ar. The number of substituents on any C is 1 or 2. In the present invention, alkylene includes but is not limited to methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), n-propylene (-CH 2 CH 2 CH 2 -), isopropylidene (-C(CH 3 ) 2 -), n-butylene (-CH 2 CH 2 CH2 CH 2 -), isobutylene, sec-butylene, tert-butylene, n-pentylene, 2-pentylene, 3-pentylene, 2-methyl-2-butylene, 3-methyl-2-butylene, 3-methyl-1-butylene, 2-methyl-1-butylene, n-hexylene, 2-hexylene, 3-hexylene, 2-methyl-2-pentylene, 3-methyl-2-pentylene, 4-methyl-2-pentylene, 3-methyl-3-pentylene, 2-methyl-3-pentylene, 2,3-dimethyl-2-butylene, 3,3-dimethyl-2-butylene, n-heptylene, n-octylene, carboxyl-substituted propylene, carboxyl-substituted n-butylene, carboxyl-substituted n-pentylene, amino-substituted propylene, amino-substituted n-butylene, amino-substituted n-pentylene.
[0116] In the present invention, -C n H 2n-2 -or-C d H 2d-2 - refers to an alkenylene group in which at least one position is unsaturated, i.e. one CC is sp 2 Double bond. The value of n is 2 to 8. In some embodiments, the value of n is 2 to 6. In other embodiments, n is 2 to 4. The value of d may be the same as or different from the value of n, and independently, the value of d is 2 to 8. In some embodiments, the value of d is 2 to 6. In other embodiments, d is 2 to 4. The alkenyl group is a straight chain alkenylene group or a branched chain alkenylene group, and in some embodiments, it is a straight chain alkenylene group. The alkenylene group is a substituted or unsubstituted alkenylene group. The H attached to any C in the substituted alkenylene group may be substituted by a substituent, and the substituent of the substituted alkenylene group is -NH 2 , -OH, -COOH or -Ar. The number of substituents on any C is 1 or 2. The alkenylene group includes groups with "anti" "positive" or "E" "Z" orientations, and specific examples include, but are not limited to, vinylene (-CH=CH-), propenylene, allylene (-CH 2 CH=CH-), butenylene and 4-methylbutenylene, 2-pentenylene, hexenylene, heptenylene, octenylene.
[0117] In some embodiments,
[0118] R 1 Selected from -C n H 2n -or-C n H 2n-2 , n = 1 to 10;
[0119] R 2 Selected from -C b H 2b-1 or -Cb H 2b+1 , b = 8 to 20;
[0120] R 3 Selected from -OH, -O-CO-(CH 2 ) c CH 3 , -C d H 2d -OH, -C d H 2d -COOH, -C d H 2d-2 -COOH, -C d H 2d -O-CO-(CH 2 ) c -CH 3 ,, c=8~20, d=1~6.
[0121] R 4 Selected from -H, -C e H 2e-1 or -C e H 2e+1 , e=8~20.
[0122] In some embodiments,
[0123] m = 0 to 6;
[0124] R 1 Selected from -CH 2 -、
[0125] R 2 Selected from -C b H 2b+1 , b = 12 to 18;
[0126] R 3 For -(CH 2 ) 2 -COOH, -CH 2 -COOH, -(CH 2 ) c -CO-(CH 2 ) c -CH 3 , c = 8 to 18;
[0127] R 4 For -C e H 2e-1 or -C e H 2e+1 , e=12~18.
[0128] In some embodiments, R 1 for R 2 For -(CH 2 ) 17 CH 3 .
[0129] In some embodiments, m=0; R 3 For -(CH 2 ) 2 -COOH; R 4 For -C e H 2e+1 , e=8~18.
[0130] The platinum complexes provided by the present invention are as follows: Formula (1) to (18), wherein x=7 to 17:
[0131]
[0132]
[0133] In the structural formulas (1) to (18) of the platinum complexes provided by the present invention, x is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17.
[0134] The platinum complex provided by the present invention is prepared by reacting a compound of formula II or a compound of formula III with a platinum compound; the platinum compound is cisplatin, carboplatin, oxaliplatin or nedaplatin, epplatin, lobaplatin and the like.
[0135]
[0136] R 5 Selected from -H, -C f H 2f+1 , -C f H 2f-1 、-Ar-C f H 2f+1 、-Ar-C f H 2f-1 、-Ar-OC f H 2f+1 Or-Ar-OC f H 2f-1 ,f=1~22;
[0137] R 6 Selected from -C g H 2g -、-C g H 2g-2 -、-C g H 2g -O- or -C g H2g-2 -O-, g = 1 to 8;
[0138] R 7 Selected from -OH, -C h H 2h+1 , -C h H 2h-1 、-Ar-C h H 2h+1 、-Ar-C h H 2h-1 、-Ar-OC h H 2h+1 Or-Ar-OC h H 2h-1 ,h=1~22;
[0139] R 8 Selected from -C i H 2i -、-C i H 2i-2 -、-Ar-C i H 2i -、-Ar-C i H 2i-2 -、-Ar-OC i H 2i -、-Ar-OC i H 2i-2 -,i=0~22;
[0140] R 9 Selected from -H, -C p H 2p+1 , -C p H 2p-1 、-Ar-C p H 2p+1 、-Ar-C p H 2p-1 、-Ar-OC p H 2p+1 、-Ar-OC p H 2p-1 ,p=0~22;
[0141] Among them, the H connected to any C can be replaced by a substituent;
[0142] Wherein, the substituent is -OH, -NH 2 , -COOH, halogen or -Ar.
[0143] R 6 and R 7 The structure of hydroxyl radicals includes at least one -COOH.
[0144] In the method provided by the present invention, the molar ratio of the compound of formula II or formula III to Pt in the platinum compound is not greater than 30:1.
[0145] In some embodiments, the molar ratio of the compound of formula II or formula III to Pt in the platinum compound is (1-8):1.
[0146] In other embodiments, the molar ratio of the compound of formula II or formula III to Pt in the platinum compound is (1-5):1.
[0147] In other embodiments, the molar ratio of the compound of formula II or formula III to Pt in the platinum compound is 2:1.
[0148] In other embodiments, the molar ratio of the compound of formula II or formula III to Pt in the platinum compound is 1:1.
[0149] The solvent used in the reaction of preparing the platinum complex is an aqueous medium.
[0150] In the embodiments provided by the present invention, the aqueous medium is water or a mannitol aqueous solution or a sodium chloride aqueous solution or a glycerol aqueous solution or a sugar-containing aqueous solution or a phosphate buffer solution, etc. (not limited to these), or can also be the above-mentioned aqueous solution containing dimethylformamide (DMF), dimethyl sulfoxide (DMSO) or ethanol.
[0151] The present invention provides an amphiphilic compound having a structure shown in Formula II:
[0152]
[0153] R 5 Selected from -H, -C f H 2f+1 , -C f H 2f-1 、-Ar-C f H 2f+1 、-Ar-C f H 2f-1 、-Ar-OC f H 2f+1 Or-Ar-OC f H 2f-1 ,f=1~22;
[0154] R 6 Selected from -C g H 2g -、-CgH 2g-2 -、-C g H 2g -O- or -CgH2g-2-O-, g = 1 to 8;
[0155] R 7Selected from -OH, -C h H 2h+1 , -C h H 2h-1 、-Ar-C h H 2h+1 、-Ar-C h H 2h-1 、-Ar-OC h H 2h+1 Or-Ar-OC h H 2h-1 ,h=1~22;
[0156] Among them, the H connected to any C can be replaced by a substituent;
[0157] Wherein, the substituent is -OH, -NH 2 , -COOH, halogen or -Ar;
[0158] R 6 and R 7 The structure of hydroxyl radicals includes at least one -COOH.
[0159] In the present invention, -C f H 2f+1 or --C h H 2h+1 It is an alkyl group, and the value of f is 1 to 22. In some embodiments, the value of f is 8 to 20. In other embodiments, f is 8 to 18 or f is 12 to 18; in other embodiments, f is 14 to 16; in some embodiments, f is 15. The value of h may be the same as or different from the value of f, and independently, the value of h is 1 to 22. In some embodiments, the value of h is 8 to 20. In other embodiments, h is 8 to 18 or h is 12 to 18; in other embodiments, h is 14 to 16; in some embodiments, h is 15. The alkyl group is a straight-chain alkyl group or a branched-chain alkyl group; in some embodiments, it is a straight-chain alkyl group. The alkyl group is a substituted or unsubstituted alkyl group. The substitution means that the H attached to any C in the alkyl group may be substituted by a substituent, and the substituent of the substituted alkyl group is -NH 2 , -OH, -COOH, halogen or -Ar. The number of substituents on any C is 1 or 2. In the present invention, -C b H 2b+1 Alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), n-propyl (n-Pr, -CH 2 CH 2 CH 3 ), isopropyl (i-Pr, -CH (CH3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), isobutyl (i-Bu, -CH 2 CH(CH 3 ) 2 ), sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methylbutyl (-CH 2 CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-butyl (-C(CH 3 ) 2 CH 2 CH 3 ), 3-methylbutyl (-CH 2 CH 2 CH(CH 3 ) 2 ), 3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), n-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-hexyl (-CH(CH 3 )CH 2 CH 2 CH 2 CH 3 ), 3-hexyl (-CH(CH 2 CH 3 )CH 2 CH2 CH 3 ), 2-methylpentyl (-CH 2 CH(CH 3 )CH 2 CH 2 CH 3 ), 2-methyl-2-pentyl (-CH(CH 3 ) 2 CH 2 CH 2 CH 3 ), 2-methyl-3-pentyl (-CH(CH 2 CH 3 )CH(CH 3 ) 2 ), 3-methylpentyl (-CH 2 CH 2 CH(CH 3 )CH 2 CH 3 ), 3-methyl-2-pentyl (-CH(CH 3 )CH(CH 3 )CH 2 CH 3 ), 3-methyl-3-pentyl (-CH(CH 3 )(CH 2 CH 3 ) 2 ), 4-methyl-2-pentyl (-CH(CH 3 )CH 2 CH(CH 3 ) 2 ), 4-methylpentyl (-CH 2 CH 2 CH 2 CH(CH 3 ) 2 ), 2,2-dimethylbutyl (-CH 2 C(CH 3 ) 2 CH 2 CH 3 ), 3,3-dimethyl-2-butyl (-CH(CH 3 )C(CH 3 ) 3 ), 3,3-dimethylbutyl (-CH 2 CH 2 C(CH 3 ) 3 ), 2,3-dimethylbutyl (-CH 2 CH(CH 3 )CH(CH 3 ) 2), 2,3-dimethyl-2-butyl (-C(CH 3 ) 2 CH(CH 3 ) 2 ), n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, and n-octadecyl.
[0160] In the present invention, -C f H 2f-1 or -C h H 2h-1 Refers to an alkenyl group in which at least one position is unsaturated, i.e. one CC is sp 2 Double bond. The value of f is 2 to 22. In some embodiments, the value of f is 8 to 20. In other embodiments, f is 8 to 18 or f is 12 to 18; in other embodiments, f is 14 to 16; in some embodiments, f is 15. The value of h may be the same as or different from the value of f, and independently, the value of h is 2 to 22. In some embodiments, the value of h is 8 to 20. In other embodiments, h is 8 to 18 or h is 12 to 18; in other embodiments, h is 14 to 16; in some embodiments, h is 15. The alkenyl group is a straight-chain alkenyl group or a branched-chain alkenyl group, and in some embodiments, it is a straight-chain alkenyl group. The alkenyl group is a substituted or unsubstituted alkenyl group. The H attached to any C in the substituted alkenyl group may be substituted by a substituent, and the substituent of the substituted alkenyl group is one or more of -NH2, -OH, -COOH, halogen or -Ar. The number of substituents on any C is 1 or two. The alkenyl group includes groups with "reverse", "normal" or "E" or "Z" orientations, and specific examples include, but are not limited to, vinyl (-CH=CH 2 ), propenyl, allyl (-CH 2 CH=CH 2 ), butenyl and 4-methylbutenyl, 2-pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl.
[0161] In the present invention, -Ar-C f H 2f+1 Refers to a -C bonded to a phenyl or aryl group f H 2f+1 , -Ar-C f H 2f-1 Refers to a -C bonded to a phenyl or aryl group f H 2f-1 , -Ar-OC f H 2f+1Refers to the -C connected to -Ar-O- f H 2f+1 , -Ar-OC f H 2f-1 Refers to the -C connected to -Ar-O- f H 2f-1 .-Ar-C h H 2h+1 Refers to a -C bonded to a phenyl or aryl group h H 2h+1 , -Ar-C h H 2h-1 Refers to a -C bonded to a phenyl or aryl group h H 2h-1 , -Ar-OC h H 2h+1 Refers to the -C connected to -Ar-O- h H 2h+1 , -Ar-OC h H 2h-1 Refers to the -C connected to -Ar-O- h H 2h-1 The -Ar- represents a monocyclic, bicyclic, and tricyclic carbon ring system containing 6-14 ring members, and at least one ring system is aromatic, wherein each ring system contains 3-7 ring members, wherein there are two connection points to the rest of the molecule. -Ar- can be phenylene, naphthyl and anthracene. And the -Ar- can be substituted or unsubstituted.
[0162] In the present invention, -C g H 2g - refers to an alkylene group, and the value of g is 1 to 8. In some embodiments, the value of g is 1 to 6. In other embodiments, g is 1 to 4; in other embodiments, g is 2 to 4; the alkylene group is a straight chain or branched chain alkylene group; in some embodiments, it is a straight chain alkylene group. The alkylene group is a substituted or unsubstituted alkylene group. The substitution means that the H attached to any C in the alkylene group can be replaced by a substituent, and the substituent of the substituted alkyl group is -NH 2 , -OH, -COOH or -Ar. The number of substituents on any C is 1 or 2. In the present invention, alkylene includes but is not limited to methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), n-propylene (-CH 2 CH 2 CH 2 -), isopropylidene (-C(CH 3 ) 2 -), n-butylene (-CH 2 CH2 CH 2 CH 2 -), isobutylene, sec-butylene, tert-butylene, n-pentylene, 2-pentylene, 3-pentylene, 2-methyl-2-butylene, 3-methyl-2-butylene, 3-methyl-1-butylene, 2-methyl-1-butylene, n-hexylene, 2-hexylene, 3-hexylene, 2-methyl-2-pentylene, 3-methyl-2-pentylene, 4-methyl-2-pentylene, 3-methyl-3-pentylene, 2-methyl-3-pentylene, 2,3-dimethyl-2-butylene, 3,3-dimethyl-2-butylene, n-heptylene, n-octylene, carboxyl-substituted propylene, carboxyl-substituted n-butylene, carboxyl-substituted n-pentylene, amino-substituted propylene, amino-substituted n-butylene, amino-substituted n-pentylene.
[0163] In the present invention, -C g H 2g-2 - refers to an alkenylene group in which at least one position is unsaturated, i.e. one CC is sp 2 Double bond. The value of g is 2 to 8. In some embodiments, the value of g is 2 to 6. In other embodiments, g is 2 to 4. The alkenyl group is a straight chain alkenylene group or a branched chain alkenylene group. In some embodiments, it is a straight chain alkenylene group. The alkenylene group is a substituted or unsubstituted alkenylene group. The H connected to any C in the substituted alkenylene group may be substituted by a substituent, and the substituent of the substituted alkenylene group is -NH 2 , -OH, -COOH or -Ar. The number of substituents on any C is 1 or 2. The alkenylene group includes groups with "reverse", "positive" or "E", "Z" orientations, and specific examples include, but are not limited to, vinylene (-CH=CH-), propenylene, allylene (-CH 2 CH=CH-), butenylene and 4-methylbutenylene, 2-pentenylene, hexenylene, heptenylene, octenylene.
[0164] In the present invention, -C g H 2g -O- or -C g H 2g-2 -O- refers to the -C connected to -O- g H 2g -or-C g H 2g-2 -.
[0165] In an embodiment of the present invention, in the amphiphilic compound:
[0166] R 1 Selected from -C f H 2f+1 , -Cf H 2f-1 , f = 8 to 18;
[0167] R 2 Selected from -C g H 2g -、-C g H 2g-1 -NH-, g = 2 to 6;
[0168] R 3 Selected from -OH, -C h H 2h+1 , -C h H 2h-1 , h=8~18.
[0169] Wherein, any H attached to C may be substituted by one or two substituents;
[0170] Wherein, the substituent is -NH 2 or -COOH.
[0171] The R 2 and R 3 The structure of hydroxyl radicals includes at least one -COOH.
[0172] In an embodiment of the present invention,
[0173] R 5 For -C f H 2f+1 , R 6 for R 7 is -OH;
[0174] or R 5 For -C f H 2f+1 , R 6 for R 7 is -OH;
[0175] or R 5 For -C f H 2f+1 , R 6 for R 7 For -C h H 2h+1 ;
[0176] or R 5 For -C f H 2f+1 , R 6 for R 7 For -C h H2h+1 ;
[0177] f=8~18; g=2~6; h=8~18.
[0178] In the embodiment of the present invention, the structure is:
[0179]
[0180] The platinum complex prepared from the compound provided by the present invention can be well combined with the membrane material of the liposome, thereby improving the encapsulation rate and drug loading of the liposome. In addition, after the platinum complex is prepared from the compound provided by the present invention, it contains a carboxyl group and has pH sensitivity. In a low pH environment (such as tumor tissue), the carboxyl group tends to be deprotonated, which is conducive to promoting the release of the drug in the tumor tissue, improving the efficacy of the drug, and reducing the toxic side effects of the drug.
[0181] The present invention also provides a liposome of a platinum complex, comprising the platinum complex provided by the present invention and a lipid membrane material; the ratio of the platinum complex to the liposome membrane material is 99:1 to 1:99.
[0182] The ratio is a mass ratio, a molar ratio or a volume ratio.
[0183] In the liposome provided by the present invention, the lipid membrane material comprises a composition of phospholipids and / or cholesterol, the mass fraction of phospholipids in the membrane material is 1 to 100 parts, and the mass fraction of cholesterol is 0 to 60 parts.
[0184] In the liposome provided by the present invention, the phospholipids include one or a combination of two or more of phosphatidylcholine, soybean lecithin, hydrogenated soybean lecithin, phosphatidylinositol, phosphatidylglycerol, dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dilauroyl phosphatidic acid, dilauroylphosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, phosphatidylserine, dilauroylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, PEGylated phospholipids, etc.
[0185] The liposome provided by the present invention may also include a long-circulation material. The long-circulation material used in the present invention is MPEG 2000 -DSPE, MPEG 5000 -DSPE, MPEG 2000 -DMPE, MPEG 5000 -DMPE, MPEG 2000 -DPPE,MPEG 5000 -DPPE, etc.
[0186] The mass fraction of the long-circulation material in the liposome provided by the invention is 0-50%.
[0187] Furthermore, the mass fraction of the long-circulating material in the liposome provided by the present invention is 6-35%.
[0188] The liposomes provided by the present invention may also include an antioxidant; the antioxidant used in the present invention is any one of L-cysteine, ascorbic acid, dl-α-tocopherol, sodium sulfite, sodium pyrosulfite or anhydrous sodium bisulfite, or a combination of two or more thereof.
[0189] In the liposome provided by the invention, the mass fraction of the antioxidant is not higher than 20%.
[0190] An isotonicity regulator can also be added to the liposome provided by the present invention. The isotonicity regulator is any one of mannitol, sorbitol, glucose, sucrose or sodium chloride, or a combination of two or more thereof.
[0191] In some embodiments, the preparation method of liposomes is: quickly injecting an appropriate amount of a solution containing a membrane material, an antioxidant and / or a long-circulation material containing an organic solvent into an aqueous solution of the platinum complex provided by the present invention, stirring at 40-50° C. for 30 minutes, and homogenizing through a liposome extruder to obtain a novel platinum liposome. In addition, the long-circulation material can also be added after the liposome is formed to modify the liposome surface.
[0192] In other embodiments, the preparation method of liposomes is as follows: take a membrane material, an antioxidant and a long-circulation material into a round-bottom flask, add an appropriate amount of an organic solvent to dissolve, add an aqueous solution of the platinum complex provided by the present invention, mechanically or ultrasonically homogenize to form a W / O emulsion, remove the organic solvent by rotary evaporation under reduced pressure, form a thin film on the container wall, inject a hydration medium, hydrate the membrane material at 40-55°C for 1-2 hours, and homogenize through a liposome extruder to obtain a novel platinum liposome.
[0193] In other embodiments, the method for preparing liposomes is as follows: taking a membrane material, an antioxidant and a platinum complex provided by the present invention into a round-bottom flask, adding an appropriate amount of an organic solvent to dissolve, removing the organic solvent by rotary evaporation under reduced pressure, forming a thin film on the container wall, injecting a hydration medium to hydrate the membrane material for 1h to 2h, and homogenizing through a liposome extruder or microfluidizer to obtain a novel platinum liposome.
[0194] In other embodiments, the method for preparing liposomes is as follows: taking a membrane material, an antioxidant and a long-circulation material into a round-bottom flask, adding an appropriate amount of an organic solvent to dissolve, adding the platinum compound provided by the present invention, ultrasonically or mechanically homogenizing to form a W / O emulsion, removing part of the organic solvent by rotary evaporation under reduced pressure, injecting a hydration medium, mechanically stirring to form W / O / W, and then removing the organic solvent by rotary evaporation under reduced pressure, and passing through a liposome extruder and microfluidizer to homogenize and disperse to obtain a novel platinum liposome.
[0195] The present invention provides a medicine for treating cancer, comprising the liposome provided by the present invention.
[0196] The medicine provided by the present invention can be used to treat cancers such as breast cancer, non-small cell lung cancer, testicular cancer, pancreatic cancer, colorectal cancer, liver cancer, ovarian cancer or head and neck cancer.
[0197] The dosage form of the drug provided by the present invention is injection (suspension or freeze-dried powder for injection), emulsion, submicron emulsion and the like.
[0198] Experiments show that the liposomes provided by the present invention can significantly increase the blood concentration of platinum compounds, prolong the retention time of drugs in the body, and can concentrate platinum drugs in cancerous organs, which can not only reduce the dosage of drugs and increase the efficacy, but also reduce the toxic and side effects of drugs, and are suitable for the treatment of various tumor diseases.
[0199] The present invention provides a compound of formula II structure, which has good biocompatibility, and the carboxyl group and the carbonyl group of the ester bond can be coordinated with platinum drugs, and the unstable coordination bond formed with the platinum drugs can increase the hydration rate of the drug in the body, thereby improving the drug efficacy. At the same time, the platinum complex prepared by the compound provided by the present invention can be well combined with the membrane material of the liposome, thereby improving the encapsulation efficiency and drug loading of the liposome. In addition, after the platinum complex is prepared by the compound provided by the present invention, it contains a carboxyl group and has pH sensitivity. In a lower pH environment (such as tumor tissue), the carboxyl group tends to be deprotonated, which is conducive to promoting the release of the drug in the tumor tissue. The liposome provided by the present invention can reduce the toxic and side effects of the drug, especially the nephrotoxicity, and maintain a certain therapeutic effect.
[0200] The reagents and instruments used in the present invention are all common commercial products and can be purchased in the market.
[0201] Example 1 Amphiphilic compounds and their preparation:
[0202]
[0203] Its preparation method is:
[0204] 1. Examples 1 to 2
[0205] In a reaction vessel, add 1.4 mol maleic anhydride, 1.0 mol octadecyl alcohol, 1000 mL cyclohexane, add 13.50 g triethylamine dropwise at room temperature, heat to 60°C for 4 hours, and then distill to dryness under reduced pressure; then add 900 mL acetone to the residue, heat to 56°C, stir for 30 minutes, cool to 40°C, stir for 1 hour, and then distill to an oily liquid under reduced pressure, cool to room temperature, add an appropriate amount of water until a solid precipitates, stir for 1 hour, filter, wash with water and petroleum ether several times, and dry the obtained solid at 60°C under vacuum for 20 hours to obtain the amphiphilic compound in Examples 1 to 2. The obtained amphiphilic compound was characterized by mass spectrometry, and the results are as follows: Figure 1-a~1-b .
[0206] Or in a reaction container, add 1.2mol of anhydride (maleic anhydride or succinic anhydride), 1.0mol of fatty alcohol (hexadecanol or octadecyl alcohol), 1000mL of cyclohexane, at room temperature, dropwise add 8.1g of triethylamine, heat to 50°C for reaction for 4h, and remove cyclohexane by vacuum distillation to obtain a solid; then add 800mL of anhydrous ethanol to the obtained solid, heat to 60°C to dissolve, stir for 30min, cool to 40°C, stir for 1h, and then vacuum distill to an oily liquid, cool to room temperature, add an appropriate amount of water to precipitate a solid, stir for 1h, filter, wash with water and petroleum ether several times, and vacuum dry the obtained solid at 60°C for 20h to obtain the amphiphilic compound in Examples 1 to 2. The obtained amphiphilic compound was characterized by NMR, IR and XRD, and the results are as follows: Figure 2-a~2-b , 3-a~3-b and 4-a~4-b.
[0207] 2. Examples 3 to 6
[0208] In a reaction vessel, add 1.4 mol of anhydride (maleic anhydride or succinic anhydride), 1.0 mol of fatty alcohol (hexadecanol or octadecyl alcohol), 1000 mL of cyclohexane, and at room temperature, dropwise add 13.50 g of triethylamine, heat to 60° C. for 4 hours, and then distill to dryness under reduced pressure; then add 900 mL of acetone to the residue, heat to 56° C., stir for 30 minutes, cool to 40° C., stir for 1 hour, then add an appropriate amount of water, cool to room temperature, stir for 1 hour, precipitate solid, filter, wash with acetone, and vacuum dry the obtained solid at 60° C. for 20 hours to obtain the amphiphilic compounds in Examples 3 to 6. The prepared amphiphilic compounds in Examples 3 to 5 were characterized by mass spectrometry, and the results are as follows: Figure 1-c~1-e , NMR characterization was performed on Examples 3 to 4, and the results were as follows Figure 2-c~2-d , infrared spectroscopy was performed on Examples 4 to 5, and the results were as follows Figure 3-c~3-d .
[0209] Or in a reaction container, add 1.2 mol of anhydride (maleic anhydride or succinic anhydride), 1.0 mol of fatty alcohol (hexadecanol or octadecyl alcohol), 1000 mL of cyclohexane, add 8.1 g of triethylamine dropwise at room temperature, heat to 50°C for reaction for 4 hours, and then remove cyclohexane by vacuum distillation to obtain a solid; then add 800 mL of anhydrous ethanol to the obtained solid, heat to 60°C to dissolve, stir for 30 minutes, cool to 40°C and keep warm for 1 hour, then add an appropriate amount of water until a small amount of solid precipitates, stir for 1 hour, cool to room temperature, precipitate solid, filter, wash with ethanol, and vacuum dry the obtained solid at 60°C for 20 hours to obtain the amphiphilic compounds in Examples 3 to 5. XRD characterization of the obtained amphiphilic compounds in Examples 3 to 5 is performed, and the results are as follows: Figure 4-c~4-e .
[0210] Examples 7 to 20 Preparation of platinum complexes
[0211] Table 1 Examples 7 to 20
[0212]
[0213]
[0214] Preparation method: add an amphiphilic compound into water, stir and dissolve it under certain conditions, add a platinum compound (the molar ratio of the amphiphilic compound to the platinum compound is 1:1-10:1), heat and stir for 4 hours, react to obtain a platinum complex, and dry to obtain a solid powder of the platinum complex.
[0215] Examples 21-31 Preparation of liposomes by reverse evaporation method
[0216] Table 2 Examples 21 to 31
[0217]
[0218]
[0219] The prescribed amount of membrane material and antioxidant are placed in a round-bottom flask, and an appropriate amount of organic solvent is added to dissolve (the organic solvent is selected from: chloroform or water-saturated ether or dichloromethane, methanol, ethanol or a mixed solvent of at least two of the solvents), and the prescribed amount of platinum complex aqueous solution is added (the volume ratio of organic solvent: water phase is 3:1-6:1), mechanically or ultrasonically homogenized to form a W / O emulsion, and the organic solvent is removed by rotary evaporation under reduced pressure to form a thin film on the container wall, and a hydration medium (physiological saline or 5% glucose or 5% sucrose or 7% sucrose or water for injection or 3% mannitol aqueous solution) is injected, and the membrane material is hydrated for 1h-2h at 40 (or 55°C), and the platinum complex liposome is obtained by homogenization through a liposome extruder or microfluidizer, and a long circulation material is added and stirred at room temperature for 1h to obtain the product.
[0220] Examples 32-34 Preparation of liposomes by ethanol injection method
[0221] Table 3 Examples 32 to 34
[0222]
[0223] Take the formulated amount of platinum complex and place it in a round-bottom flask, add appropriate amount of water and 7% sucrose, and quickly inject the formulated amount of ethanol solution of membrane material after dissolution, stir at 40-50°C for 30 minutes, homogenize through a liposome extruder, add appropriate amount of water and 7% sucrose to dilute to a certain concentration to obtain a new platinum liposome.
[0224] Example 35 Preparation of liposomes by thin film dispersion method
[0225] Table 4 Example 35
[0226]
[0227] Take a formulated amount of membrane material, antioxidant, long-circulation material, and a formulated amount of platinum complex and place them in a round-bottom flask, add an appropriate amount of chloroform to dissolve, remove the organic solvent by rotary evaporation under reduced pressure, form a thin film on the container wall, inject a hydration medium (water for injection), hydrate the membrane material at 40-55° C. for 1-2 hours, and homogenize through a liposome extruder to obtain a new type of platinum liposome.
[0228] Example 36 Preparation of liposomes by double emulsion method
[0229] Table 5 Example 36
[0230]
[0231] The membrane material and antioxidant in a formulated amount are placed in a round-bottom flask, an appropriate amount of ether is added to dissolve, a formulated amount of platinum compound aqueous solution (the volume ratio of the organic phase to the aqueous phase is 3:1) is added, ultrasonic or mechanical homogenization is performed to form a W / O emulsion, a part of the organic solvent is removed by rotary evaporation under reduced pressure, a 7% sucrose aqueous solution is injected, mechanical stirring is performed to form a W / O / W, the organic solvent is removed by rotary evaporation under reduced pressure, and the novel platinum liposome is obtained by homogenization and dispersion through a liposome extruder and a microfluidizer.
[0232] Example 37 Liposome Quality Inspection
[0233] The morphology of the platinum complex liposomes prepared by the present invention was observed by electron microscopy, and the particle size and distribution of the liposomes were measured by Zetasizer Nano ZS90 laser particle size analyzer. The encapsulation efficiency of the liposomes prepared by the present invention was calculated by the method provided in the Chinese Pharmacopoeia. The results are shown in Table 6:
[0234] Table 6 Liposome particle size and encapsulation efficiency investigation results
[0235] Example No. Average particle size (nm) Encapsulation rate (%) 21 123.4 91.3 22 119.6 95.1 23 102.8 94.5 24 107.7 94.4 25 106.5 93.6 26 117.3 91.2 27 102.2 98.1 28 96.7 92.5 29 109.4 97.2 30 115.8 92.6 31 114.1 94.9 32 96.4 90.1 33 105.3 92.5 34 124.8 90.6
[0236] Figure 5 , Figure 6 This is the morphology and particle size spectrum of the liposomes prepared in Example 24. The detection results of the liposomes prepared in other examples are similar to this.
[0237] The results show that the particle size of the novel platinum complex liposome preparation provided by the present invention is between 90 and 150 nm, and the encapsulation efficiency is between 90 and 98%. Different from the liposomes reported in existing literature and patents, the platinum liposome has the characteristics of high encapsulation efficiency, good stability and strong anticancer activity.
[0238] Example 38 Preparation of reference liposomes
[0239] According to the method in the literature (CN106995465B), a platinum complex a (structure as shown in a) was prepared with cisplatin and an amphiphilic compound b (structure as shown in b) as a platinum complex containing an amide bond, and its liposome was prepared according to Example 31 in the patent (CN106995465B), wherein the amount of platinum complex a was equivalent to 12 mg of cisplatin, the amount of membrane material was 20 mg of cholesterol, 200 mg of soybean lecithin, the amount of antioxidant VE was 5 mg, the hydration medium was water for injection, and the preparation method was the reverse evaporation method. The particle size of the prepared liposome was 101.7 nm, and the encapsulation efficiency was 92.76%.
[0240]
[0241] Example 39: Pharmacological Efficacy of Liposomes
[0242] 1. Tumor inhibition rate
[0243] Physiological saline, cisplatin for injection, liposomes prepared in Examples 32 and 33, and reference liposomes (liposomes prepared in Example 38) were used as experimental materials. SPF-grade KM mice were taken, male, 6-8 weeks old, and weighed 18-22 g. Take logarithmically growing sarcoma S180 cells, and adjust the single cell concentration to (1-5)×106cell / mL. The S180 cell suspension was inoculated subcutaneously in the right axilla of the mouse, 0.2 mL per mouse, to establish an axillary inoculation model of the S180 sarcoma strain. Tumor-bearing mice were randomly divided into 7 groups, 7 mice in each group, namely, a physiological saline group, a cisplatin control group for injection, and an experimental group (respectively given platinum complex liposomes and reference liposomes provided in Examples 32 and 33 of the present invention), group numbers, tail veins of each group, cisplatin control group, experimental group, first administered once every two days, administered four times, and then administered once every three days, administered four times, with dosages of 5 mg / kg and 10 mg / kg, respectively. After administration, the survival status of the mice was observed daily. The mice were killed on the 20th day after administration, the tumors were removed, the surface was washed with saline, dried with filter paper, weighed, and the tumor inhibition rate was calculated as follows:
[0244] Tumor inhibition rate (%) = (average tumor weight of the control group - average tumor weight of the test group) ÷ average tumor weight of the control group × 100
[0245] The experimental results show that the tumor growth of the drug-treated group is slower than that of the control group. Compared with the cisplatin control group, the experimental group can significantly inhibit the growth of the tumor and significantly prolong the survival time of the tumor-bearing mice. The tumor weight and related parameters are shown in Table 8, and the survival rate is shown in Table 9.
[0246] Table 8 Tumor weight and tumor inhibition rate of KM mice bearing S180 sarcoma injected with 5mg / kg and 10mg / kg experimental materials through tail vein
[0247] Example No. Average tumor weight (g) Inhibition rate (%) Normal saline 4.5520 — Example 32 (5 mg / kg) 1.7021 62.61 Example 32 (10 mg / kg) 0.6931 84.77 Example 33 (5 mg / kg) 1.7236 62.14 Example 33 (10 mg / kg) 0.7373 83.80 Reference liposomes (5 mg / kg) 1.7429 61.71 Reference liposomes (10 mg / kg) 0.7562 83.39
[0248] The survival rate results of KM mice bearing S180 sarcoma are shown in Figure 7 (7a-7d) and Table 9.
[0249] Table 9 Survival rate of KM mice bearing sarcoma S180 at 20 days
[0250] Example No. Survival rate (%) Normal saline 85.71 Cisplatin control group (5 mg / kg) 0 Cisplatin control group (10 mg / kg) 0 Example 32 (5 mg / kg) 85.71 Example 32 (10 mg / kg) 85.71 Example 33 (5 mg / kg) 85.71 Example 33 (10 mg / kg) 85.71 Reference liposomes (5 mg / kg) 71.43 Reference liposomes (10 mg / kg) 71.43
[0251] The results showed that the liposomes prepared in Example 32 had a tumor inhibition rate comparable to that of the reference liposomes of the same dose, and a survival rate significantly higher than that of the reference liposomes, indicating that the liposomes provided by the present invention can not only effectively inhibit tumor growth and improve the survival rate of mice, but also significantly reduce the toxicity of cisplatin and improve the survival status of mice. This also shows that platinum complexes containing ester bonds are less toxic than those containing amide bonds.
[0252] The results of kidney tissue sections of KM mice bearing sarcoma S180 are shown in Figure 8 .
[0253] The results showed that the kidneys of mice in the CDDP-S group showed glomerular atrophy, dilation of the renal capsule, and obvious renal damage, while no obvious renal damage was observed in the liposomes provided by the present invention, indicating that the liposomes provided by the present invention can significantly reduce the nephrotoxicity of cisplatin.
[0254] Example 40 Liposome Safety
[0255] 1. Survival status and weight
[0256] KM mice were randomly divided into groups, 10 mice in each group, with numbers within the group, fasted for 12 hours before administration, and allowed to drink water freely. The mice were injected with 10 mg / kg of normal saline, commercial cisplatin control group, and liposomes obtained in Example 33 through the tail vein. The mice and body weight changes were observed and recorded for 14 consecutive days after administration.
[0257] Results Fig. 9 and Fig.10 The results showed that compared with the cisplatin control group, the liposome mice prepared in Example 33 had significantly reduced weight loss, good survival status, and significantly improved survival rate, indicating that the toxicity of the cisplatin complex liposome was significantly reduced.
[0258] 2.LD 50
[0259] KM mice were randomly divided into 14 dose groups, 10 mice in each group. The mice were group-fed for 1 day, and the normal status of each group of mice was observed. The weight of each mouse was weighed before administration. The dose of Example 33 and reference liposomes injected intravenously to each mouse was calculated based on the body weight. The group interval was 1.3, and the concentrations administered to each dose group were 26, 33.8, 43.94, 57.12, 74.26, 96.54, and 125.50 mg / kg, respectively. Within 7 days after administration, the number of deaths of mice in each group was recorded. During the experiment, the animals in each group were group-fed and fed freely. The number of animal deaths was entered into LD 50 Software to calculate LD 50 .
[0260] The results showed that the LD of the liposomes prepared in Example 33 50 The value is 68.01 mg / kg, and the LD of the reference liposome (implementation 38) 50 The value is 45.90 mg / kg, so the liposomes prepared in Example 33 are safer than the reference liposomes. It is further proved that the platinum complexes containing ester bonds are less toxic than those containing amide bonds. It is believed that the former may have a less toxic metabolite in the body than the latter, so it is safer.
[0261] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A platinum complex, characterized in that: The structure is as follows: Among them, x=7~17.
2. A liposome of a platinum complex, characterized in that: The invention comprises the platinum complex and lipid membrane material as claimed in claim 1; the ratio of the platinum complex and lipid membrane material is (99:1) to (1:99); the ratio is a mass ratio or a molar ratio.
3. The liposome according to claim 1, characterized in that The lipid membrane material comprises a composition of phospholipids and / or cholesterol, wherein the mass fraction of phospholipids in the membrane material is 1 to 100 parts, and the mass fraction of cholesterol is 0 to 60 parts.
4. The liposome according to claim 3, characterized in that The phospholipids include one or a combination of two or more of lecithin, soybean lecithin, hydrogenated soybean lecithin, phosphatidylinositol, phosphatidylglycerol, dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dilauroyl phosphatidic acid, dilauroylphosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, phosphatidylserine, dilauroylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, and PEGylated phospholipids.
5. Use of the platinum complex according to claim 1 or the liposome according to any one of claims 2 to 4 in the preparation of anticancer drugs.
